An Antibody-armored Dendritic Cell in Patients With Solid Tumors
NCT07479667 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8
Last updated 2026-03-18
Summary
This study is a single-arm, open-label, single-administration dose-escalation study.
Conditions
- Solid Cancers
- Adjuvant Therapy
Interventions
- BIOLOGICAL
-
Armored Dendritic Cell Injection
Armored dendritic cells are administered via multiple subcutaneous injections.
Sponsors & Collaborators
-
Shanghai Cell Therapy Group Co.,Ltd
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-05
- Primary Completion
- 2028-12-31
- Completion
- 2029-06-30
Countries
- China
Study Locations
More Related Trials
-
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
NCT05235607 ·Status: UNKNOWN ·Phase: PHASE1
-
Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer
NCT03113019 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer
NCT00795977 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients
NCT01530698 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine
NCT04672473 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Dendritic Cell Vaccination for Patients with Solid Tumors
NCT01291420 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dendritic Cell Vaccination in Patients With Advanced Melanoma
NCT03092453 ·Status: COMPLETED ·Phase: PHASE1
-
Biological Therapy in Treating Patients With Advanced Cancer
NCT00005956 ·Status: COMPLETED ·Phase: NA
-
DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs
NCT06329908 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
NCT00683670 ·Status: COMPLETED ·Phase: PHASE1
-
Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors
NCT04765462 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
RNA-Loaded Dendritic Cell Cancer Vaccine
NCT00087984 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia
NCT05000801 ·Status: RECRUITING ·Phase: NA
-
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
NCT04214717 ·Status: UNKNOWN ·Phase: NA
-
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
NCT00576537 ·Status: COMPLETED ·Phase: PHASE2
-
Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden
NCT03671720 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Melanoma Patients Immunized with Natural DenDritic Cells
NCT02993315 ·Status: COMPLETED ·Phase: PHASE3
-
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
NCT03047811 ·Status: UNKNOWN ·Phase: NA
-
Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
NCT04115761 ·Status: RECRUITING ·Phase: PHASE2
-
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
NCT00405327 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
NCT03190811 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
NCT01973322 ·Status: COMPLETED ·Phase: PHASE2
-
MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer
NCT04078269 ·Status: COMPLETED ·Phase: PHASE1
-
Neoantigen-expanded Autologous Immune Cell Therapy
NCT05020119 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
NCT02318394 ·Status: COMPLETED ·Phase: PHASE1